Molecure S.A. (MOC WAR) stock market data APIs
zł5.906
-0.28(-4.7%)
as of July 10, 2026
Try our APIs with
free plan!
Molecure S.A. Financial Data Overview
Price chart is built with
Anychart
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
Prev. Close
5.906
Open
5.6268
High
5.9214
Low
5.5562
52 wk Range
4.98-9.06
Market Cap
139 M
Shares Outstanding
24 724 K
Revenue
6 519 K
EPS
-0.1969
Beta
1.028
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Molecure S.A. data using free add-ons & libraries
Get Molecure S.A. Fundamental Data
Molecure S.A. Fundamental data includes:
- Net Revenue: 6 519 K
- EBITDA: -15 631 912
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Molecure S.A. News
New
Molecure Announces Third Quarter 2023 Financial Results and Pipeline Highlights
U.S. Food and Drug Administration (FDA) approval to conduct a Phase II clinical trial for novel chitinase inhibitor OATD-01 in pulmonary sarcoidosis with first patient expected to be dosed in fourth q...
Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum
Molecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential for breakthrough therapies for incurable diseasesCompleted...
The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch
Press release The U.S. Food and Drug AdministrationGives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01is Ready for Launch Molecurecan proceed with clinica...
Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies
Press release Molecure completes successful Secondary Public Offering (SPO) ofapproximately PLN50 million (USD12 million)with proceeds to be used to fund and builda first in class, sustainable pipeli...
Get Molecure S.A. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
